DOCSLIB.ORG

21 CFR Ch. I (4–1–19 Edition) § 310.545

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

§ 310.545 21 CFR Ch. I (4–1–19 Edition) for marketing. In the absence of an ap- Chloroxylenol proved new drug application or abbre- Cloxyquin viated new drug application, such prod- Coal tar uct is also misbranded under section Dibenzothiophene Estrone 502 of the act. Magnesium aluminum silicate (c) Clinical investigations designed Magnesium sulfate to obtain evidence that any drug prod- Phenol uct labeled, represented, or promoted Phenolate sodium for OTC use as a smoking deterrent is Phenyl salicylate safe and effective for the purpose in- Povidone-iodine tended must comply with the require- Pyrilamine maleate ments and procedures governing the Resorcinol (as single ingredient) use of investigational new drugs set Resorcinol monoacetate (as single ingre- dient) forth in part 312 of this chapter. Salicylic acid (over 2 up to 5 percent) (d) After May 7, 1991, any such OTC Sodium borate drug product containing cloves, cori- Sodium thiosulfate ander, eucalyptus oil, ginger (Ja- Tetracaine hydrochloride maica), lemon oil (terpeneless), licorice Thymol root extract, menthol, methyl salicy- Vitamin E late, quinine ascorbate, silver nitrate, Zinc oxide and/or thymol initially introduced or Zinc stearate initially delivered for introduction into Zinc sulfide interstate commerce that is not in (2) Anticaries drug products—(i) Ap- compliance with this section is subject proved as of May 7, 1991. to regulatory action. After December 1, 1993, any such OTC drug product con- Hydrogen fluoride Sodium carbonate taining lobeline (in the form of lobeline Sodium monofluorophosphate (6 percent sulfate or natural lobelia alkaloids or rinse) Lobelia inflata herb), povidone-silver ni- Sodium phosphate trate, silver acetate, or any other in- gredients initially introduced or ini- (ii) Approved as of October 7, 1996. tially delivered for introduction into Calcium sucrose phosphate interstate commerce that is not in Dicalcium phosphate dihydrate compliance with this section is subject Disodium hydrogen phosphate 1 to regulatory action. Phosphoric acid 1 Sodium dihydrogen phosphate [58 FR 31241, June 1, 1993] Sodium dihydrogen phosphate monohydrate Sodium phosphate, dibasic anhydrous rea- § 310.545 Drug products containing gent 1 certain active ingredients offered over-the-counter (OTC) for certain (3) Antidiarrheal drug products—(i) Ap- uses. proved as of May 7, 1991. (a) A number of active ingredients Aluminum hydroxide have been present in OTC drug prod- Atropine sulfate ucts for various uses, as described Calcium carbonate below. However, based on evidence cur- Carboxymethylcellulose sodium rently available, there are inadequate Glycine Homatropine methylbromide data to establish general recognition of Hyoscyamine sulfate the safety and effectiveness of these in- Lactobacillus acidophilus gredients for the specified uses: Lactobacillus bulgaricus (1) Topical acne drug products. Opium, powdered Opium tincture Alcloxa Paregoric Alkyl isoquinolinium bromide Phenyl salicylate Aluminum chlorohydrex Scopolamine hydrobromide Aluminum hydroxide Zinc phenolsulfonate Benzocaine Benzoic acid Boric acid 1 These ingredients are nonmonograph ex- Calcium polysulfide cept when used to prepare acidulated phos- Calcium thiosulfate phate fluoride treatment rinses identified in Camphor § 355.10(a)(3) of this chapter. 38 VerDate Sep<11>2014 15:24 Aug 05, 2019 Jkt 247074 PO 00000 Frm 00048 Fmt 8010 Sfmt 8010 Y:\SGML\247074.XXX 247074 rmajette on DSKBCKNHB2PROD with CFR Food and Drug Administration, HHS § 310.545 (ii) Approved as of April 19, 2004; April Cedar leaf oil (topical) 18, 2005, for products with annual sales Creosote, beechwood (topical) less than $25,000. Ephedrine (oral) Ephedrine hydrochloride (oral) Attapulgite, activated Ephedrine sulfate (oral) Bismuth subnitrate Racephedrine hydrochloride (oral/topical) Calcium hydroxide Calcium polycarbophil (C) Approved as of April 11, 2007; Oc- Charcoal (activated) tober 11, 2007, for products with annual Pectin sales less than $25,000. Any ingre- Polycarbophil dient(s) labeled with claims or direc- Potassium carbonate tions for use for sinusitis or for relief Rhubarb fluidextract of nasal congestion associated with si- (4) Antiperspirant drug products—(i) nusitis. Ingredients—Approved as of May 7, 1991. (iii) Expectorant drug products. Alum, potassium Ammonium chloride Aluminum bromohydrate Antimony potassium tartrate Aluminum chloride (alcoholic solutions) Beechwood creosote Aluminum chloride (aqueous solution) (aer- Benzoin preparations (compound tincture of osol only) benzoin, tincture of benzoin) Aluminum sulfate Camphor Aluminum sulfate, buffered (aerosol only) Chloroform Sodium aluminum chlorohydroxy lactate Eucalyptol/eucalyptus oil (ii) Approved as of December 9, 2004; Horehound June 9, 2005, for products with annual Iodides (calcium iodide anyhydrous, hydroid- sales less than $25,000. ic acid syrup, iodized lime, potassium io- dide) Aluminum sulfate buffered with sodium alu- Ipecac minum lactate Ipecac fluidextract Ipecac syrup (5) [Reserved] Menthol/peppermint oil (6) Cold, cough, allergy, bronchodilator, Pine tar preparations (extract white pine and antiasthmatic drug products—(i) compound, pine tar, syrup of pine tar, com- Antihistamine drug products—(A) Ingre- pound white pine syrup, white pine) dients. Potassium guaiacolsulfonate Sodium citrate Methapyrilene hydrochloride Squill preparations (squill, squill extract) Methapyrilene fumarate Terpin hydrate preparations (terpin hydrate, Thenyldiamine hydrochloride terpin hydrate elixir) (B) Ingredients. Tolu preparations (tolu, tolu balsam, tolu balsam tincture) Phenyltoloxamine dihydrogen citrate Turpentine oil (spirits of turpentine) Methapyrilene hydrochloride Methapyrilene fumarate (iv) Bronchodilator drug products—(A) Thenyldiamine hydrochloride Approved as of October 2, 1987. (ii) Nasal decongestant drug products— Aminophylline (A) Approved as of May 7, 1991. Belladonna alkaloids Euphorbia pilulifera Allyl isothiocyanate Metaproterenol sulfate Camphor (lozenge) Methoxyphenamine hydrochloride Creosote, beechwood (oral) Pseudoephedrine hydrochloride Eucalyptol (lozenge) Pseudoephedrine sulfate Eucalyptol (mouthwash) Theophylline, anhydrous Eucalyptus oil (lozenge) Theophylline calcium salicylate Eucalyptus oil (mouthwash) Menthol (mouthwash) Theophylline sodium glycinate Peppermint oil (mouthwash) (B) Approved as of January 29, 1996. Thenyldiamine hydrochloride Any combination drug product con- Thymol Thymol (lozenge) taining theophylline (e.g., theophylline Thymol (mouthwash) and ephedrine, or theophylline and Turpentine oil ephedrine and phenobarbital). (C) Approved as of June 19, 1996. Any (B) Approved as of August 23, 1995. ingredient(s) in a pressurized metered- Bornyl acetate (topical) dose inhaler container. 39 VerDate Sep<11>2014 15:24 Aug 05, 2019 Jkt 247074 PO 00000 Frm 00049 Fmt 8010 Sfmt 8010 Y:\SGML\247074.XXX 247074 rmajette on DSKBCKNHB2PROD with CFR § 310.545 21 CFR Ch. I (4–1–19 Edition) (D) Approved as of October 29, 2001. Alcohol Any oral bronchodilator active ingre- Aluminum hydroxide dient (e.g., ephedrine, ephedrine hydro- Amylase Anise seed chloride, ephedrine sulfate, Aromatic powder racephedrine hydrochloride, or any Asafetida other ephedrine salt) in combination Aspergillus oryza enzymes (except lactase with any analgesic(s) or analgesic-anti- enzyme derived from Aspergillus oryzae) pyretic(s), anticholinergic, antihis- Bacillus acidophilus tamine, oral antitussive, or stimulant Bean active ingredient. Belladonna alkaloids (7) Dandruff/seborrheic dermatitis/psori- Belladonna leaves, powdered extract Betaine hydrochloride asis drug products. Bismuth subcarbonate Alkyl isoquinolinium bromide Bismuth subgallate Allantoin Black radish powder Benzalkonium chloride Blessed thistle (cnicus benedictus) Benzethonium chloride Buckthorn Boric acid Calcium gluconate Calcium undecylenate Capsicum Captan Capsicum, fluid extract of Chloroxylenol Carbon Colloidal oatmeal Cascara sagrada extract Cresol, saponated Catechu, tincture Ethohexadiol Catnip Eucalyptol Chamomile flowers Juniper tar Charcoal, wood Lauryl isoquinolinium bromide Chloroform Menthol Cinnamon oil Mercury oleate Cinnamon tincture Methylbenzethonium chloride Citrus pectin Methyl salicylate Diastase Phenol Diastase malt Phenolate sodium Dog grass Pine tar Elecampane Povidone-iodine Ether Resorcinol Fennel acid Sodium borate Galega Sodium salicylate Ginger Thymol Glycine Undecylenic acid Hydrastis canadensis (golden seal) Hectorite (8) Digestive aid drug products—(i) Ap- Horsetail proved as of May 7, 1991. Huckleberry Hydrastis fluid extract Bismuth sodium tartrate Hydrochloric acid Calcium carbonate Iodine Cellulase Iron ox bile Dehydrocholic acid Johnswort Dihydroxyaluminum sodium carbonate Juniper Duodenal substance Kaolin, colloidal Garlic, dehydrated Knotgrass Glutamic acid hydrochloride Lactic acid Hemicellulase Lactose Homatropine methylbromide Lavender compound, tincture of Magnesium hydroxide Linden Magnesium trisilicate Lipase Ox bile extract Lysine hydrochloride Pancreatin Mannitol Pancrelipase Mycozyme Papain Peppermint oil Myrrh, fluid extract of Pepsin Nettle Sodium bicarbonate Nickel-pectin Sodium citrate Nux vomica extract Sorbitol Orthophosphoric acid Papaya, natural (ii) Approved as of November 10, 1993. Pectin 40 VerDate Sep<11>2014 15:24 Aug 05, 2019 Jkt 247074 PO 00000 Frm 00050 Fmt 8010 Sfmt 8010 Y:\SGML\247074.XXX 247074 rmajette on DSKBCKNHB2PROD with CFR Food and Drug Administration, HHS § 310.545 Peppermint Methapyrilene hydrochloride Peppermint
Recommended publications
  • Toxicological Evaluation Purifog.Pdf

    Toxicological Evaluation Purifog.Pdf

    Università degli Studi di Torino Prof Valter Maurino Dipartimento di Chimica phone: +39 0116705218 fax: +39 0116707615 Via P. Giuria, 7 10125 Torino Italy e-mail: [email protected] Toxicological evaluation of “PURIFOG” Page 2/24 Short term/single exposure .................................................................................................................................... 17 Inhalation ............................................................................................................................................................... 17 Oral administration LD50 ..................................................................................................................................... 17 Dermal application LD50 ...................................................................................................................................... 18 Skin irritation ........................................................................................................................................................ 18 Sensitisation .......................................................................................................................................................... 18 Mucous membranes and eye ................................................................................................................................ 18 LD and LC50 reported values for Benzyldimethyldecylammonium chloride ................................................... 19 LD and LC50 reported values for Dimethyldioctadecylammonium
  • Wo 2010/127231 A2

    Wo 2010/127231 A2

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 4 November 2010 (04.11.2010) WO 2010/127231 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every AOlN 33/12 (2006.01) A61K 31/14 (2006.01) kind of national protection available): AE, AG, AL, AM, AOlN 25/04 (2006.01) CIlD 3/26 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, AOlP 1/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US2010/033 148 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 30 April 2010 (30.04.2010) NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (25) Filing Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/174,724 1 May 2009 (01 .05.2009) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, (71) Applicant (for all designated States except US): SIG¬ TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, NAL INVESTMENT AND MANAGEMENT CO.
  • Toxicological Evaluation and Limit Values for 2-Ethylhexyl Acryate, Propylene Carbonate, Quaternary Ammonium Compounds, Triglyci

    Toxicological Evaluation and Limit Values for 2-Ethylhexyl Acryate, Propylene Carbonate, Quaternary Ammonium Compounds, Triglyci

    Environmental Project No. 555 2000 Miljøprojekt Toxicological Evaluation and Limit Values for 2-Ethylhexyl acryate, Propylene carbonate, Quaternary ammonium compounds, triglycidyl isocyanurate and tripropyleneglycol diacrylate Pia Berthelsen, Vibe Beltoft, Inger Thorup, Inge Søborg and Elsa Nielsen The Institute of Food Safety and Toxicology Danish Veterinary and Food Administration The Danish Environmental Protection Agency will, when opportunity offers, publish reports and contributions relating to environmental research and development projects financed via the Danish EPA. Please note that publication does not signify that the contents of the reports necessarily reflect the views of the Danish EPA. The reports are, however, published because the Danish EPA finds that the studies represent a valuable contribution to the debate on environmental policy in Denmark. Contents Preface 5 Principles for setting of limit values for chemical substances 7 2-Ethylhexyl acrylate 11 Propylene carbonate 35 Quaternary ammonium compounds 51 Triglycidyl isocyanurate 81 Tripropyleneglycol diacrylate 111 3 4 Preface This series of reports constitutes a part of the work related to the setting of health based limit values for chemical substances in air, soil and drinking water. In this report, the toxicological documentation for the setting of limit values for 2-ethylhexyl acrylate, propylene carbonate, quaternary ammo- nium compounds, triglycidyl isocyanurate, and tripropyleneglycol diac- rylate are presented. For every substance, the following items are
  • Rpt POL-TOXIC AIR POLLUTANTS 98 BY

    Rpt POL-TOXIC AIR POLLUTANTS 98 BY

    SWCAA TOXIC AIR POLLUTANTS '98 by CAS ASIL TAP SQER CAS No HAP POLLUTANT NAME HAP CAT 24hr ug/m3 Ann ug/m3 Class lbs/yr lbs/hr none17 BN 1750 0.20 ALUMINUM compounds none0.00023 AY None None ARSENIC compounds (E649418) ARSENIC COMPOUNDS none0.12 AY 20 None BENZENE, TOLUENE, ETHYLBENZENE, XYLENES BENZENE none0.12 AY 20 None BTEX BENZENE none0.000083 AY None None CHROMIUM (VI) compounds CHROMIUM COMPOUN none0.000083 AY None None CHROMIUM compounds (E649962) CHROMIUM COMPOUN none0.0016 AY 0.5 None COKE OVEN COMPOUNDS (E649830) - CAA 112B COKE OVEN EMISSIONS none3.3 BN 175 0.02 COPPER compounds none0.67 BN 175 0.02 COTTON DUST (raw) none17 BY 1,750 0.20 CYANIDE compounds CYANIDE COMPOUNDS none33 BN 5,250 0.60 FIBROUS GLASS DUST none33 BY 5,250 0.60 FINE MINERAL FIBERS FINE MINERAL FIBERS none8.3 BN 175 0.20 FLUORIDES, as F, containing fluoride, NOS none0.00000003 AY None None FURANS, NITRO- DIOXINS/FURANS none5900 BY 43,748 5.0 HEXANE, other isomers none3.3 BN 175 0.02 IRON SALTS, soluble as Fe none00 AN None None ISOPROPYL OILS none0.5 AY None None LEAD compounds (E650002) LEAD COMPOUNDS none0.4 BY 175 0.02 MANGANESE compounds (E650010) MANGANESE COMPOU none0.33 BY 175 0.02 MERCURY compounds (E650028) MERCURY COMPOUND none33 BY 5,250 0.60 MINERAL FIBERS ((fine), incl glass, glass wool, rock wool, slag w FINE MINERAL FIBERS none0.0021 AY 0.5 None NICKEL 59 (NY059280) NICKEL COMPOUNDS none0.0021 AY 0.5 None NICKEL compounds (E650036) NICKEL COMPOUNDS none0.00000003 AY None None NITROFURANS (nitrofurans furazolidone) DIOXINS/FURANS none0.0013
  • Toxicological Evaluation of “PURIFOG Hypo” Page 1/30 Spett.Le FONDERIA MESTIERI Via Almese, 72 - 10093 Collegno (TO) - IT Tel

    Toxicological Evaluation of “PURIFOG Hypo” Page 1/30 Spett.Le FONDERIA MESTIERI Via Almese, 72 - 10093 Collegno (TO) - IT Tel

    Università degli Studi di Torino Prof Valter Maurino Dipartimento di Chimica phone: +39 0116705218 fax: +39 0116707615 Via P. Giuria, 7 10125 Torino Italy e-mail: [email protected] Toxicological evaluation of “PURIFOG Hypo” Page 1/30 Spett.le FONDERIA MESTIERI via Almese, 72 - 10093 Collegno (TO) - IT Tel. +393355977772 / +393494388929 [email protected] Toxicological evaluation of “PURIFOG Hypo” INDEX EXECUTIVE SUMMARY ....................................................................................................................................... 3 PRODUCT TO BE EVALUATED ........................................................................................................................ 3 TOXICOLOGICAL EVALUATION OF “PURIFOG HYPO” ......................................................................... 3 DIPROPYLENE GLYCOL (CAS# 25265-71-8) ........................................................................................................ 4 2, TOXICITY SUMMARY .......................................................................................................................................... 4 3 SKIN IRRITATING AND SENSITIZING EFFECTS ....................................................................................................... 5 3 REPRODUCTIVE AND DEVELOPMENTAL TOXICOLOGY ......................................................................................... 5 3 SKIN, EYE, AND RESPIRATORY IRRITATIONS .......................................................................................................
  • Pharmacy Data Management Drug Exception List

    Pharmacy Data Management Drug Exception List

    Pharmacy Data Management Drug Exception List Patch PSS*1*127 updated the following drugs with the listed NCPDP Multiplier and NCPDP Dispense Unit. These two fields were added as part of this patch to the DRUG file (#50). Please refer to the Release notes for ePharmacy/ECME Enhancements for Pharmacy Release Notes (BPS_1_5_EPHARMACY_RN_0907.PDF) on the VistA Documentation Library (VDL). The IEN column reflects the IEN for the VA PRODUCT file (#50.68). The ePharmacy Change Control Board provided the following list of drugs with the specified NCPDP Multiplier and NCPDP Dispense Unit values. This listing was used to update the DRUG file (#50) with a post install routine in the PSS*1*127 patch. NCPDP File 50.68 NCPDP Dispense IEN Product Name Multiplier Unit 2 ATROPINE SO4 0.4MG/ML INJ 1.00 ML 3 ATROPINE SO4 1% OINT,OPH 3.50 GM 6 ATROPINE SO4 1% SOLN,OPH 1.00 ML 7 ATROPINE SO4 0.5% OINT,OPH 3.50 GM 8 ATROPINE SO4 0.5% SOLN,OPH 1.00 ML 9 ATROPINE SO4 3% SOLN,OPH 1.00 ML 10 ATROPINE SO4 2% SOLN,OPH 1.00 ML 11 ATROPINE SO4 0.1MG/ML INJ 1.00 ML 12 ATROPINE SO4 0.05MG/ML INJ 1.00 ML 13 ATROPINE SO4 0.4MG/0.5ML INJ 1.00 ML 14 ATROPINE SO4 0.5MG/ML INJ 1.00 ML 15 ATROPINE SO4 1MG/ML INJ 1.00 ML 16 ATROPINE SO4 2MG/ML INJ 1.00 ML 18 ATROPINE SO4 2MG/0.7ML INJ 0.70 ML 21 ATROPINE SO4 0.3MG/ML INJ 1.00 ML 22 ATROPINE SO4 0.8MG/ML INJ 1.00 ML 23 ATROPINE SO4 0.1MG/ML INJ,SYRINGE,5ML 5.00 ML 24 ATROPINE SO4 0.1MG/ML INJ,SYRINGE,10ML 10.00 ML 25 ATROPINE SO4 1MG/ML INJ,AMP,1ML 1.00 ML 26 ATROPINE SO4 0.2MG/0.5ML INJ,AMP,0.5ML 0.50 ML 30 CODEINE PO4 30MG/ML
  • FOI 161-112 Document 1

    FOI 161-112 Document 1

    \/ Fw: IDC - Mercury L fy [SEC=:UNCLASSIFIED] 09/12/2010 04:23 PM - This is the fi rst of two emails I will send - this is our response to the questions posed by the UNEP f""I secretariat after the first in June. INC ...., C Kind regards, QJ E :::l ..*******��***************�************ u o International Coordination Team c Office of Parliamentary and Strategic Support Therapeutic Goods Administration E-mail: [email protected] ----- Forwarded n 09/12/20"10 04:21 PM ---_. To 'ilenvironmentgov,au> · cc !ilenvironment.gov,au>, environment.gov,au>_ "" 11/11/2010 .. .. 02:14 PM Subject Re: IDC - Mercury LBI- Friday 23 July [SEC=UNCLASSIFIED} Dear_ Please find attached TGA's contribution to the mercury data gaps identified by the UNEP Secretariat. Should you have any queries or concerns relating to tllis information, we would be very happy to discuss these at our meeting tomorrow (Friday 12 November at 3pm), TGA participants at tomorrow's meeting will be: Devices Authorisation Office of Scientific Evaluation Services _ill also be there, representing the International Coordination team. Please note that we are correctly identified as stakeholders for the Regulation sector (arrangements for labelling products containing mercury), but mistakenly included as a stakeholder for the sector for uni ntentional emission (biomedical waste i Ilcineration), Kind regards, International Coordination Tearn Office of Parliamentary aild Strategic Support Therapeutic Goods Administration E�mail: [email protected] o - Mercury in ther�peutic products - Response for UNEP INC Oct 201 O.DOCX Dear Colleagues FOl owlng u� ercury �BI meeting on FridLY'23 July, we would li ke to t from t� �C � M request for )tell assl�� ce In addressing the mercury data gaps that the UNEP Secretariat has identified.
  • Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act

    Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act

    Updated June 07, 2021 Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Three categories of bulk drug substances: • Category 1: Bulk Drug Substances Under Evaluation • Category 2: Bulk Drug Substances that Raise Significant Safety Risks • Category 3: Bulk Drug Substances Nominated Without Adequate Support Updates to Categories of Substances Nominated for the 503B Bulk Drug Substances List1 • Add the following entry to category 2 due to serious safety concerns of mutagenicity, cytotoxicity, and possible carcinogenicity when quinacrine hydrochloride is used for intrauterine administration for non- surgical female sterilization: 2,3 o Quinacrine Hydrochloride for intrauterine administration • Revision to category 1 for clarity: o Modify the entry for “Quinacrine Hydrochloride” to “Quinacrine Hydrochloride (except for intrauterine administration).” • Revision to category 1 to correct a substance name error: o Correct the error in the substance name “DHEA (dehydroepiandosterone)” to “DHEA (dehydroepiandrosterone).” 1 For the purposes of the substance names in the categories, hydrated forms of the substance are included in the scope of the substance name. 2 Quinacrine HCl was previously reviewed in 2016 as part of FDA’s consideration of this bulk drug substance for inclusion on the 503A Bulks List. As part of this review, the Division of Bone, Reproductive and Urologic Products (DBRUP), now the Division of Urology, Obstetrics and Gynecology (DUOG), evaluated the nomination of quinacrine for intrauterine administration for non-surgical female sterilization and recommended that quinacrine should not be included on the 503A Bulks List for this use. This recommendation was based on the lack of information on efficacy comparable to other available methods of female sterilization and serious safety concerns of mutagenicity, cytotoxicity and possible carcinogenicity in use of quinacrine for this indication and route of administration.
  • Assessment of the Antibiotic Resistance Effects of Biocides

    Assessment of the Antibiotic Resistance Effects of Biocides

    Scientific Committee on Emerging and Newly Identified Health Risks SCENIHR Assessment of the Antibiotic Resistance Effects of Biocides The SCENIHR adopted this opinion at the 28th plenary on 19 January 2009 after public consultation. 1 Antibiotic Resistance Effects of Biocides About the Scientific Committees Three independent non-food Scientific Committees provide the Commission with the scientific advice it needs when preparing policy and proposals relating to consumer safety, public health and the environment. The Committees also draw the Commission's attention to the new or emerging problems which may pose an actual or potential threat. They are: the Scientific Committee on Consumer Products (SCCP), the Scientific Committee on Health and Environmental Risks (SCHER) and the Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR), and are made up of external experts. In addition, the Commission relies upon the work of the European Food Safety Authority (EFSA), the European Medicines Evaluation Agency (EMEA), the European Centre for Disease prevention and Control (ECDC) and the European Chemicals Agency (ECHA). SCENIHR Questions concerning emerging or newly-identified risks and on broad, complex or multi- disciplinary issues requiring a comprehensive assessment of risks to consumer safety or public health and related issues not covered by other Community risk-assessment bodies. In particular, the Committee addresses questions related to potential risks associated with interaction of risk factors, synergic effects, cumulative effects, antimicrobial resistance, new technologies such as nanotechnologies, medical devices, tissue engineering, blood products, fertility reduction, cancer of endocrine organs, physical hazards such as noise and electromagnetic fields and methodologies for assessing new risks.
  • Mercury Contamination in Man and His Environment

    Mercury Contamination in Man and His Environment

    TECHNICAL REPORTS SERIES No. 137 Mercury Contamination in Man and his Environment A JOINT UNDERTAKING BY THE INTERNATIONAL LABOUR ORGANISATION. THE FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS. THE WORLD HEALTH ORGANIZATION AND THE INTERNATIONAL ATOMIC ENERGY AGENCY J WJ INTERNATIONAL ATOMIC ENERGY AGENCY, VIENNA, 1972 MERCURY CONTAMINATION IN MAN AND HIS ENVIRONMENT TECHNICAL REPORTS SERIES No. 137 MERCURY CONTAMINATION IN MAN AND HIS ENVIRONMENT A JOINT UNDERTAKING BY THE INTERNATIONAL LABOUR ORGANISATION, THE FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS, THE WORLD HEALTH ORGANIZATION AND THE INTERNATIONAL ATOMIC ENERGY AGENCY INTERNATIONAL ATOMIC ENERGY AGENCY VIENNA, 1972 MERCURY CONTAMINATION IN MAN AND HIS ENVIRONMENT IAEA, VIENNA, 1972 STI/DOC/lO/137 Printed by the IAEA in Austria July 1972 FOREWORD In May 1967, at a Symposium organized by the International Atomic Energy Agency in Amsterdam, the special problems of food and environ- mental contamination by mercury were discussed by world experts on the subject and by representatives of FAO, WHO and IAEA. One of the recom- mendations made by this meeting was that the international organizations of the United Nations family should assist in the collection and distribution of information on environmental mercury. Subsequently, the organizations concerned agreed that a handbook on mercury contamination would be es- pecially useful. This would deal with sources of mercury in relation to man and his environment; with physical and biological transfer processes that determine its distribution; with analytical methods for determining mercury and its compounds as environmental contaminants; with actual concentrations of mercury found in the environment, in living organisms and in man; and with its toxicology in animals and man.
  • Phenylmercuric Salts 1657 Ingrowing Toenails

    Phenylmercuric Salts 1657 Ingrowing Toenails

    Phenol/Phenylmercuric Salts 1657 Ingrowing toenails. Liquefied phenol (88%) ablation has been water; miscible with alcohol, with acetone, and with glycerol; Incompatibility. The incompatibilities of phenylmercuric salts performed as an alternative to surgical avulsion in the treatment slightly soluble in arachis oil and in olive oil. Store in a dry place, are described under Phenylmercuric Nitrate, below. of ingrowing toenails.1,2 A systematic review3 concluded that in airtight containers at a temperature of 8° to 15°. Protect from simple nail avulsion combined with treating the nail-bed with light. Phenylmercuric Borate (rINN) phenol was more effective at preventing symptomatic recurrence Borato de fenilmercurio; Fenilgyvsidabrio boratas; Fenil-higany- of ingrowing toenails than cutting out the nail-bed. However, Incompatibility. The activity of phenoxyethanol may be re- there was a significant increase in postoperative infections when duced by interaction with nonionic surfactants and possibly by borát; Fenylhydrargyriumborát; Fenylkvicksilverborat; Fenylortę- phenol was used. adsorption onto PVC. ciowy boran; Fenyylimerkuriboraatti; Hydrargyrum Phenylobori- 1. Bostanci S, et al. Chemical matricectomy with phenol for the Profile cum; Phenomerborum; Phenylhydrargyri boras; Phénylmercure, treatment of ingrowing toenail: a review of the literature and fol- Phenoxyethanol is effective against strains of Pseudomonas aer- borate de. low-up of 172 treated patients. Acta Derm Venereol 2001; 81: Фенилмеркурборат 181–3. uginosa but less so against other Gram-negative and Gram-pos- 2. Andreassi A, et al. Segmental phenolization for the treatment of itive bacteria. It has been used as a preservative in cosmetics and C6H5HgOH,C6H5HgOB(OH)2 =633.2 or C6H5HgOH, ingrowing toenails: a review of 6 years experience.
  • Heavy-Atom Kinetic Isotope Effects

    Heavy-Atom Kinetic Isotope Effects

    A UNITED STATES DEPARTMENT OF COMMERCE NATL PUBLICATION NBS SPECIAL PUBLICATION 349 •Nr., of** Heavy-Atom Kinetic Isotope Effects An Indexed Bibliography U.S. EPARTMENT OF COMMERCE National Bureau of jQ^^^tandards 00 SI — NATIONAL BUREAU OF STANDARDS The National Bureau of Standards^ was established by an act of Congress March 3, 1901. The Bureau's overall goal is to strengthen and advance the Nation's science and technology and facilitate their effective application for public benefit. To this end, the Bureau conducts research and provides: (1) a basis for the Nation's physical measure- ment system, (2) scientific and technological services for industry and government, (3) a technical basis for equity in trade, and (4) technical services to promote public safety. The Bureau consists of the Institute for Basic Standards, the Institute for Materials Research, the Institute for Applied Technology, the Center for Computer Sciences and Technology, and the Office for Information Programs. THE INSTITUTE FOR BASIC STANDARDS provides the central basis within the United States of a complete and consistent system of physical measurement; coordinates that system with measurement systems of other nations; and furnishes essential services leading to accurate and uniform physical measurements throughout the Nation's scien- tific community, industry, and commerce. The Institute consists of a Center for Radia- tion Research, an Office of Measurement Services and the following divisions: Applied Mathematics—Electricity—Heat—Mechanics—Optical Physics—^Linac